Abstract：Objective: To analyze the application effect of Tianmai Xiaoke Tablets combined with empagliflozin in patients with diabetes mellitus complicated with heart failure. Methods: A total of 102 patients diagnosed with T2DM and heart failure, admitted to Shijiazhuang Maternal and Child Health Hospital and the 980th Hospital of the Joint Logistic Support Force of the People's Liberation Army of China between June 2021 and May 2024, were enrolled and randomly assigned to two groups using a random number generator: an observation group and a control group, with 51 patients in each. The control group underwent standard treatment, whereas the observation group received additional Tianmai Xiaoke Tablet and empagliflozin therapy. Following 12 weeks of treatment, alterations in blood glucose indices, cardiac function parameters, myocardial tissue protein indexes, and quality of life were assessed in both groups, and therapeutic outcomes were compared. Results: Post-treatment, both groups exhibited reductions in the fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2hPG), and glycated hemoglobin (HbA1c) levels compared to baseline (control group: t / P=5.408/<0.001, 5.567/<0.001, 4.162/<0.001; observation group: t / P=11.63/<0.001, 11.734/<0.001, 9.224/<0.001), with the observation group demonstrating greater decreases across all three indices (t / P=5.575/<0.001, 4.385/<0.001, 3.480/<0.001). Additionally, LVEDD decreased while LVEF increased in both groups post-treatment (control group: t / P=6.231/<0.001 for LVEDD reduction, t / P=2.548/0.014 for LVEF increase; observation group: t / P=7.783/<0.001 for left ventricular end-diastolic diameter (LVEDD) reduction, t / P=5.808/<0.001 for left ventricular ejection Fraction (LVEF) increase), with the observation group showing more pronounced changes (t / P=5.493/<0.001, 2.585/0.011). After treatment, the levels of silent information regulator 2 homologous protein 1 (SIRT1) and uncoupled protein 2 (UCP2) in the control group had no significant changes (t / P=0.141/0.888, 0.445/0.657), while the levels of SIRT1 in the observation group increased significantly (t / P=-4.944/<0.001), and the levels of UCP2 decreased significantly (t / P=17.841/<0.001), both of which were higher than those in the control group (t / P=-5.687/<0.001, 14.305/<0.001). Furthermore, SF-36 scale scores improved across all dimensions in both groups after treatment (control group: t=9.987, 9.259, 8.465, 12.371, 9.769, 9.699, 11.276, 8.964, P<0.001 for all; Observation group: t =19.307, 22.258, 12.985, 19.43, 21.002, 17.785, 19.74, 16.632, all P<0.001), with the observation group scoring higher in every dimension (t =7.959, 11.148, 5.765, 10.055, 7.871, 6.789, 12.113, 7.468, all P<0.001). Ultimately, the observation group exhibited a higher overall treatment efficacy compared to the control group (P<0.05). Conclusion: Using a combination of Tianmai Xiaoke Tablet and Enggligin for treating diabetes patients with heart failure results in more effective blood sugar regulation, enhancement of cardiac function, betterment of quality of life, and improved therapeutic outcomes.
韩蕊, 张瑜, 白维娟, 王飞. 天麦消渴片联合恩格列净在糖尿病合并心衰患者中的应用效果[J]. 河北医学, 2025, 31(11): 1924-1929.
HAN Rui, ZHANG Yu, et al. The Application Effect of Tianmai Xiaoke Tablets Combined with Empagliflozin in Patients with Diabetes Mellitus Complicated with Heart Failure. HeBei Med, 2025, 31(11): 1924-1929.
2025, Vol. 31 
冀公网安备13080202000786号